Weight loss drug makers still have huge upside, and the market overreacted to RFK Jr. named to top health role, BMO says
Investors are fearful RFK Jr.'s critical stance on weight loss drugs could impact pricing or Medicare coverage, but BMO says ...
RFK Jr. heading HHS could be a game changer, says Solus' Dan Greenhaus
Dan Greenhaus, Solus chief strategist and economist, joins 'Closing Bell' to discuss navigating an indecisive market, the ...
BioSpace2h
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough Month, More
Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
WVXU27m
Former VP Mike Pence calls Trump's HHS nomination 'deeply concerning'
Pence's opposition to RFK Jr. had nothing to do with the nominee's stance on many health issues that have already been raised ...
RFK Jr. may start a food and drug ‘culture war.’ Investors are running for cover.
President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services is one ...